Overview


According to FutureWise analysis, the market for Antiviral Drugs to reach US$ 60,500 million by 2028.

Antiviral drugs are a class of medications used to treat viral infections. Viruses are different from bacteria and other microorganisms because they cannot reproduce or carry out metabolic processes on their own. Instead, they require a host cell to replicate and spread. Antiviral drugs work by targeting specific steps in the viral replication cycle, either by inhibiting viral entry into host cells, interfering with viral genome replication, or preventing the assembly and release of new virions.

One type of antiviral drug is nucleoside/nucleotide analogs, which mimic the molecular makeup of natural nucleotides and interfere with viral replication by inhibiting the synthesis of viral DNA or RNA. Examples of nucleoside analogs include acyclovir and tenofovir. Another type of antiviral drug is protease inhibitors, which target viral enzymes that are essential for the replication of certain viruses, such as HIV and hepatitis C virus (HCV). Examples of protease inhibitors include ritonavir and lopinavir/ritonavir, and glecaprevir/pibrentasvir. Integrase inhibitors are another class of antiviral drugs that target the enzyme integrase, which is required to integrate viral DNA into host cells. Examples of integrase inhibitors include raltegravir and dolutegravir. Direct-acting antivirals are a newer class of antiviral drugs that target specific viral proteins or enzymes, such as polymerase inhibitors for HCV or neuraminidase inhibitors for influenza virus.

FutureWise Market Research has published a report that provides an insightful analysis of Antiviral Drugs Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts projects that Antiviral Drugs Market will experience a significant growth. According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.
  • Gilead Sciences
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • AbbVie
  • Merck & Co. Inc.
  • Johnson And Johnson Services Inc.
  • Bristol-Myers Squibb Company
  • Cipla Inc.
  • Aurobindo Pharma
  • Dr Reddy’s Laboratories Ltd.
  • Glenmark Pharmaceuticals Ltd.

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Antiviral Drugs Market:

  • In January 2022, To treat people in India with COVID-19, Lupin introduced the antiviral medication Molnupiravir under the trade name Molnulup.

The antiviral drugs market has been experiencing dynamic growth due to several factors. One of the key drivers of this market is the increasing prevalence of viral diseases, such as HIV, hepatitis, and influenza. As the global population expands and becomes more interconnected, the risk of viral outbreaks and pandemics also increases, driving demand for antiviral drugs. Another factor influencing the growth of the antiviral drugs market is the increasing availability of effective antiviral therapies. Advances in biotechnology and pharmaceutical research have led to the development of new and more effective antiviral drugs, including direct-acting antivirals (DAAs) for hepatitis C and integrase inhibitors for HIV. This has created new opportunities for pharmaceutical companies to develop and market these drugs to a growing patient population. In addition to these factors, government initiatives and policies have also played a role in driving the antiviral drugs market. For example, the US government has launched several initiatives to combat viral diseases, such as the President's Emergency Plan for AIDS Relief and the National HIV/AIDS Strategy. These initiatives have helped increase awareness of viral diseases and improve access to antiviral therapies, which has driven demand for these drugs.

However, there are some challenges the antiviral drugs market faces, such as the high cost of antiviral therapies and the emergence of drug-resistant viral strains. These challenges have led to calls for more affordable and accessible antiviral therapies, as well as continued research and development of new drugs to combat emerging viral threats.

In conclusion, the antiviral drugs market is expected to continue experiencing dynamic growth in the coming years, driven by the increasing prevalence of viral diseases, advances in antiviral therapies, and government initiatives to combat viral outbreaks and pandemics.

By Type

  • Branded
  • Generic

By Drug Class

  • DNA Polymerase Inhibitors
  • Reverse Transcriptase Inhibitors
  • Protease Inhibitors
  • Neuraminidase Inhibitors
  • Others

By Application

  • HIV
  • Hepatitis
  • Herpes
  • Influenza
  • Others                

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered the highest share in the market in 2022 because of the presence of reputed market competitors and the rising frequency of viral illnesses like HIV. According to HIV.gov, roughly 1.2 million individuals in the United States had HIV in October 2022. Around 13 % are not aware of the condition and require HIV testing. Additionally, the market's expansion in the North American region may be ascribed to key companies' growing R&D expenditures and the FDA's recent resounding approval of several drugs. For instance, the FDA contemplated approving the first two oral COVID-19 antivirals, PAXLOVID from Pfizer and MOLNUPIRAVIR from Merck & Co., in December 2021.
  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants
  • Growth prospects
  • SWOT analysis
  • Key market trends
  • Key data-points affecting market growth
  • To provide with an exhaustive analysis on the global antiviral drugs market by type, by drug class, by application and by region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East and Africa
  • To record, evaluate and analyze competitive landscape mapping- product launches, technological advancements, mergers and expansions
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1 . Years Considered for the Study
         3.2 . Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1 . Secondary Data
          1.1.1 . Key Data from Secondary Sources
         1.2 . Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.  Antiviral Drugs Market Variables, Trends and Scope

    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework on Country Level
         6.1 . Reimbursement Framework
         6.2 . Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1 . Market Driver Analysis
          1.1.1. Increasing focus of Antiviral Drugs Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2 . Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3 . Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Market Analysis tools
    •   1. Industry Analysis - Porter’s
         1.1 . Supplier Power
         1.2 . Buyer Power
         1.3 . Substitution Threat
         1.4 . Threat from new entrants
         1.5 . Competitive Rivalry
        2. Pestel Analysis
         2.1 . Political Landscape
         2.2 . Environmental Landscape
         2.3 . Social landscape
         2.4 . Technology landscape
         2.5 . Legal Landscape
  • 7.   Antiviral Drugs Market, By Type Historical Analysis 2017-2022 and Forecast 2023-2031 (USD million)

    •   1. Branded
        2. Generic

  • 8.   Antiviral Drugs Market, By Drug Class Historical Analysis 2017-2022 and Forecast 2023-2031 (USD million)

    •   1. DNA Polymerase Inhibitors
        2. Reverse Transcriptase Inhibitors
        3. Protease Inhibitors
        4. Neuraminidase Inhibitors
        8.5 . Others

  • 9.   Antiviral Drugs Market, By Application Historical Analysis 2017-2022 and Forecast 2023-2031 (USD million)

    •   1. HIV
        2. Hepatitis
        3. Herpes
        4. Influenza
        5. Others

  • 10.   North America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Mn) Analysis By Country, 2017-2022
         2.1. U.S.
         2.2. Canada
         2.3. Mexico
         2.4 . Rest of North America
        10.3 . Market Size (USD Mn) Forecast for North America 2023-2031

  • 11.   Latin America Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Regional Market Trends
        3. Historical Market Size (US$ Mn) Analysis By Country, 2017-2022
         3.1. Brazil
         3.2. Uruguay
         3.3 . Argentina
         3.4. Rest of Latin America
        11.4 . Market Size (US$ Mn) Forecast for Latin America 2023-2031

  • 12.   Europe Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (US$ Mn) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5 . Switzerland
         2.6. Spain
         2.7. Russia
         2.8. Poland
         2.9. Rest of Western Europe
        12.3 . Market Size (US$ Mn) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   13.1 . Introduction
        13.2 . Historical Market Size (USD Mn) Analysis By Country, 2017-2022
         2.1 . Japan
         2.2 . China
         2.3 . Singapore
         2.4 . Korea
         2.5 . India
         2.6 . Australia and New Zealand
         2.7 . ASEAN
         2.8 . Rest of Asia Pacific
        13.3 . Market Size (US$ Mn) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   14.1 . Introduction
        14.2 . Historical Market Size (USD Mn) Analysis By Country, 2017-2022
         2.1 . GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        14.3 . Market Size (US$ Mn) Forecast for MEA 2023-2031

  • 15.  Market Share Analysis and Competitive Landscape

    •        1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 16.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Product Type and Technology Portfolio, Financial Layouts)

    •  16.1 . Gilead Sciences
         1.1. Company Overview (HQ, Business Segments, Employee Strength)
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. F. Hoffmann-La Roche AG
         2.1. Company Overview (HQ, Business Segments, Employee Strength)
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. GlaxoSmithKline plc
         3.1. Company Overview (HQ, Business Segments, Employee Strength)
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. AbbVie
         4.1. Company Overview (HQ, Business Segments, Employee Strength)
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. MerckCo. Inc.
         5.1. Company Overview (HQ, Business Segments, Employee Strength)
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Johnson and Johnson Services Inc.
                  6.1. Company Overview (HQ, Business Segments, Employee Strength)
                  6.2. Product Portfolio
             6.3. SWOT Analysis
          6.4. Financial Overview
          6.5. Strategic Overview
             16. 7. Bristol-Myers Squibb Company
                  7.1. Company Overview (HQ, Business Segments, Employee Strength)
                  7.2. Product Portfolio
             7.3. SWOT Analysis
          7.4. Financial Overview
          7.5. Strategic Overview
              8. Cipla Inc.
                  8.1. Company Overview (HQ, Business Segments, Employee Strength)
                  8.2. Product Portfolio
             8.3. SWOT Analysis
          8.4. Financial Overview
          8.5. Strategic Overview
              9. Aurobindo Pharma
                  9.1. Company Overview (HQ, Business Segments, Employee Strength)
                  9.2. Product Portfolio
             9.3. SWOT Analysis
          9.4. Financial Overview
          9.5. Strategic Overview
            10. Dr Reddy’s Laboratories Ltd.
                  10.1. Company Overview (HQ, Business Segments, Employee Strength)
                  10.2. Product Portfolio
             10.3. SWOT Analysis
          10.4. Financial Overview
          10.5. Strategic Overview
             11. Glenmark Pharmaceuticals Ltd.
                  11.1. Company Overview (HQ, Business Segments, Employee Strength)
                  11.2. Product Portfolio
             11.3. SWOT Analysis
          11.4. Financial Overview
          11.5. Strategic Overview

  • 17.   Competitive Intelligence and Competitive Matrix
    •   17.1 . Competitive Intelligence
        17.2 . Competitive Matrix
  • 18.   Major Deals and Strategic Alliances Analysis
    •   18.1 . Joint ventures
        18.2 . Mergers and acquisitions
        18.3 . Licensing and partnerships
        18.4 . Technology Collaborations
        18.5 . Strategic Divestments
        18.6 . Market Entry Strategies
  • 19.  Pre and Post COVID-19 Impact

    •        1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 20.   Key Market Takeaway Points from the Market Analysts at Future Market Analytics

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11